Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Esperion Therapeutics has received a consensus recommendation of "Moderate Buy" from five brokerages, with one hold rating and four buy ratings.
• The company's stock has a market capitalization of $554.46 million, with a recent price of $2.75 and a 12-month high of $3.94.
• Esperion Therapeutics reported better-than-expected quarterly earnings of ($0.02) per share, surpassing the consensus estimate by $0.15, alongside revenue of $82.39 million.

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $7.00.

A number of research analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Friday. Wall Street Zen cut Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, August 25th.

Esperion Therapeutics Stock Down 3.3%

Shares of Esperion Therapeutics stock traded down $0.09 during trading on Friday, reaching $2.66. 10,708,890 shares of the company were exchanged, compared to its average volume of 6,037,875. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $3.94. The business has a 50-day moving average price of $1.98 and a 200-day moving average price of $1.42. The firm has a market capitalization of $536.31 million, a price-to-earnings ratio of -5.43, a P/E/G ratio of 61.77 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.15. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%.The business had revenue of $82.39 million during the quarter, compared to analysts' expectations of $62.55 million. On average, equities research analysts forecast that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wyoming grew its stake in Esperion Therapeutics by 36.2% in the second quarter. State of Wyoming now owns 122,532 shares of the biopharmaceutical company's stock valued at $121,000 after acquiring an additional 32,596 shares during the period. Brevan Howard Capital Management LP lifted its holdings in shares of Esperion Therapeutics by 139.0% in the second quarter. Brevan Howard Capital Management LP now owns 78,715 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 45,782 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Esperion Therapeutics by 7.4% in the second quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company's stock valued at $72,000 after purchasing an additional 4,979 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Esperion Therapeutics by 238.3% in the second quarter. Qube Research & Technologies Ltd now owns 485,603 shares of the biopharmaceutical company's stock valued at $478,000 after purchasing an additional 342,067 shares in the last quarter. Finally, Diametric Capital LP lifted its holdings in shares of Esperion Therapeutics by 57.8% in the second quarter. Diametric Capital LP now owns 678,824 shares of the biopharmaceutical company's stock valued at $668,000 after purchasing an additional 248,648 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.